Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shengjing Hospital
With
First Hospital of China Medical University
Liaoning Cancer Hospital & Institute
Fudan University
This cohort study employs an ambispective design, with both retrospective and prospective phases.
Age
18–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18-79 years, male or female;
Confirmed primary solid malignant tumor (non-small cell lung cancer) by histopathological or cytological examination, clinically staged as stage III-IV according to the 8th edition of AJCC/UICC staging system;
Planned to receive or receiving first-line standard systemic therapy (including chemotherapy, anti-PD-1/PD-L1 immune checkpoint inhibitors, or EGFR-TKI targeted therapy);
Standardized baseline 18F-FDG PET/CT examination completed within 2 weeks before the first anti-tumor treatment, with complete whole-body/thoracic metabolic parameters (SUVmax, MTV, etc.) and thin-slice enhanced/non-enhanced CT image sequences; images with satisfactory quality and without severe respiratory motion artifacts;
At least one measurable solid tumor target lesion per RECIST v1.1;
Complete baseline clinicopathological characteristics, baseline laboratory data, and standardized long-term follow-up records (including progression-free survival and overall survival status);
Written informed consent signed by the patient or legal representative (waiver of informed consent for the retrospective part has been approved by the institutional review board).
You may not be if
Unclear pathological diagnosis, non-primary malignant tumor, or concomitant active second primary malignant tumor at other sites;
Prior surgical resection, radical radiotherapy, or systemic anti-tumor therapy (neoadjuvant therapy, conversion therapy, etc.) targeting the primary lesion before baseline PET/CT examination;
Severe uncontrolled systemic metabolic diseases (e.g., severe diabetes with fasting blood glucose \> 11.1 mmol/L that significantly interferes with 18F-FDG uptake distribution), severe hepatic or renal insufficiency, or severe infection that renders the patient intolerant to examination and follow-up;
Incomplete PET/CT imaging data, contrast medium injection failure, extremely low image signal-to-noise ratio, or severe respiratory motion artifacts/intracorporeal metal implant artifacts which prevent accurate lesion delineation and radiomic analysis;
Severe missing of key clinical follow-up data, loss to follow-up, or inability to accurately determine objective treatment response and survival endpoints.
